死菌药2期失败,股价暴跌,微生物组企业裁员削减成本 | 产业要闻
本期看点
Evelo更新临床进展及商业计划 ExeGi药物EXE-346 IND申报获批 Q702联合K药1b/2期临床首例患者接受治疗 Rise药物R-3750 1期临床IND申报获受理 Visura宣布完成400万美元的B轮融资 赛诺菲和CytoReason扩大合作瞄准IBD
Evelo更新临床进展及商业计划
作者:Evelo Biosciences
解读:Richard
来源:Evelo Biosciences官网
发布日期:2023-02-01
内容要点
原文链接:
https://ir.evelobio.com/news-releases/news-release-details/evelo-biosciences-provides-clinical-and-business-updates
ExeGi药物EXE-346 IND申报获批
作者:ExeGi Pharma
解读:一颗坏豆
来源:Biospace
发布日期:2023-01-26
内容要点
原文链接:
https://www.biospace.com/article/releases/exegi-pharma-announces-clearance-of-investigational-new-drug-ind-application-for-exe-46-a-live-biotherapeutic-biologic-drug/
Q702联合K药1b/2期临床首例患者接受治疗
作者:Qurient
解读:Richard
来源:Business newswire
发布日期:2023-01-30
内容要点
原文链接:
https://www.businesswire.com/news/home/20230202005011/en/Qurient-Announces-Dosing-of-First-Patient-in-Q702-in-Combination-with-KEYTRUDA%C2%AE-in-a-Phase-1b2-Clinical-Study-for-the-Treatment-of-Patients-with-Solid-Tumors
Rise药物R-3750 1期临床IND申报获受理
作者:Rise Therapeutics
解读:Jack Chen
来源:Biospace
发布日期:2023-01-31
内容要点
原文链接:
https://www.biospace.com/article/releases/rise-therapeutics-announces-fda-clearance-of-its-ind-application-to-initiate-a-phase-1-study-of-an-oral-immunotherapy-for-the-treatment-of-ulcerative-colitis/
Visura宣布完成400万美元的B轮融资
作者:Biospace
解读:Alex Zhang
来源:Biospace
发布日期:2023-01-18
内容要点
原文链接:
https://www.biospace.com/article/releases/visura-announces-closing-of-series-b-financing/
赛诺菲和CytoReason扩大合作瞄准IBD
作者:Kate Goodwin
解读:海思邈
来源:Biospace
发布日期:2023-01-29
内容要点
原文链接:
https://www.biospace.com/article/sanofi-and-cytoreason-to-target-inflammatory-diseases-in-expanded-collaboration/